Clinical characteristics of patients with AML and healthy control subjects included in this study
| Healthy control subjects . | Age, y/sex . | Patients with AML . | Age, y/sex . | Diagnosis . | Cytogenetics . | Mutation status . | Previous treatment . | AML blast % . |
|---|---|---|---|---|---|---|---|---|
| HD 1 | 50/F | AML 1 | 74/M | Relapse (2nd) | inv(16), +8, −20q | DNMT3A | 2 | 5 |
| HD 2 | 50/F | AML 2 | 62/F | Refractory (s/p 2nd relapse) | t(6;14)(q25;q22) | DNMT3A, CUX1, U2AF1, NPM1 | 2 | 9 |
| HD 3 | 48/M | AML 3 | 54/F | Refractory | −7q, +8, −20q | U2AF1 | 2 | 13 |
| HD 4 | 34/M | AML 4 | 30/M | Refractory | t(9;11)(p21.3;q23.3) | None | 3 | 30 |
| HD 5 | 60/M | AML 5 | 71/M | Relapse (late, 1st) | Normal | DNMT3A, TET2 | 1 | 4 |
| HD 6 | 59/M | AML 6 | 51/F | Relapse (early, 1st) | −5q, −7p, −14q, +20q, +21 | NRAS, RUNX1, TP53 | 2 | 33 |
| HD 7 | 65/M | AML 7 | 56/F | Refractory | Normal | DNMT3A, TET2, U2AF1 | 3 | 12 |
| HD 8 | 60/F | AML 8 | 69/M | Refractory | −7, −5q, +1q | TP53, ASXL1 | 1 | 30 |
| HD 9 | 57/F | AML 9 | 62/F | Refractory | Normal | EZH2, SETBP1, ASXL1, STAG2, RUNX1 | 3 | 9 |
| HD 10 | 49/F | AML 10 | 81/M | Refractory | +8 | SRSF2, ASXL1, RUNX1 | 2 | 10 |
| Healthy control subjects . | Age, y/sex . | Patients with AML . | Age, y/sex . | Diagnosis . | Cytogenetics . | Mutation status . | Previous treatment . | AML blast % . |
|---|---|---|---|---|---|---|---|---|
| HD 1 | 50/F | AML 1 | 74/M | Relapse (2nd) | inv(16), +8, −20q | DNMT3A | 2 | 5 |
| HD 2 | 50/F | AML 2 | 62/F | Refractory (s/p 2nd relapse) | t(6;14)(q25;q22) | DNMT3A, CUX1, U2AF1, NPM1 | 2 | 9 |
| HD 3 | 48/M | AML 3 | 54/F | Refractory | −7q, +8, −20q | U2AF1 | 2 | 13 |
| HD 4 | 34/M | AML 4 | 30/M | Refractory | t(9;11)(p21.3;q23.3) | None | 3 | 30 |
| HD 5 | 60/M | AML 5 | 71/M | Relapse (late, 1st) | Normal | DNMT3A, TET2 | 1 | 4 |
| HD 6 | 59/M | AML 6 | 51/F | Relapse (early, 1st) | −5q, −7p, −14q, +20q, +21 | NRAS, RUNX1, TP53 | 2 | 33 |
| HD 7 | 65/M | AML 7 | 56/F | Refractory | Normal | DNMT3A, TET2, U2AF1 | 3 | 12 |
| HD 8 | 60/F | AML 8 | 69/M | Refractory | −7, −5q, +1q | TP53, ASXL1 | 1 | 30 |
| HD 9 | 57/F | AML 9 | 62/F | Refractory | Normal | EZH2, SETBP1, ASXL1, STAG2, RUNX1 | 3 | 9 |
| HD 10 | 49/F | AML 10 | 81/M | Refractory | +8 | SRSF2, ASXL1, RUNX1 | 2 | 10 |
F, female; HD, healthy donor; M, male.